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We describe a scalable artiﬁcial bilayer lipid membrane platform for rapid
electrophysiological screening of ion channels and transporters. A passive pumping
method is used to ﬂow microliter volumes of ligand solution across a suspended
bilayer within a microﬂuidic chip. Bilayers are stable at ﬂow rates up to  0.5ll/
min. Phospholipid bilayers are formed across a photolithographically deﬁned
aperture made in a dry ﬁlm resist within the microﬂuidic chip. Bilayers are stable
for many days and the low shunt capacitance of the thin ﬁlm support gives low-
noise high-quality single ion channel recording. Dose-dependent transient blocking
of a-hemolysin with b-cyclodextrin (b-CD) and polyethylene glycol is demon-
strated and dose-dependent blocking studies of the KcsA potassium channel with
tetraethylammonium show the potential for determining IC50 values. The assays
are fast (30 min for a complete IC50 curve) and simple and require very small
amounts of compounds (100lg in 15ll). The technology can be scaled so that mul-
tiple bilayers can be addressed, providing a screening platform for ion channels,
transporters, and nanopores. V C 2015 AIP Publishing LLC.
[http://dx.doi.org/10.1063/1.4905313]
I. INTRODUCTION
Ion channel proteins are present in all biological cell membranes and play an important
role in physiological processes, with abnormal channel activity contributing to a wide range of
diseases.
1–5 As important drug targets, ion channels are of considerable interest to the pharma-
ceutical industry.
6 Classical electrophysiology measurements can provide detailed information
about the structure-function relationship of ion channels and their modulation by pharmaceutical
drugs.
Planar bilayer lipids are now widely used for single ion channel electrophysiology. Parallel
recording techniques from multiple bilayers are being pursued
7,8 and improvements in bilayer
stability and the ease of bilayer formation have been demonstrated, for example, through the
use of smaller apertures over micro-cavities and nanopores.
9–12 Although small apertures are
preferable for stable bilayers, the smaller integrated Ag/AgCl electrode can restrict recording
time to a few hours.
9,12 Furthermore, the probability of ion-channel incorporation into bilayers
is proportional to the surface area,
13 therefore large-area bilayers are desirable but these are of-
ten unstable. Stable large-area bilayers have been produced using tapered apertures of
20–30lm diameter made from Si3N4 septa of 240nm thickness
14 but silicon-based materials
introduce undesirable noise. However, shaped apertures can also be fabricated, one at the time,
in the negative photoresist SU8 using two-photon direct write lithography.
15
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compartment design, these techniques do not allow access to both sides of the bilayer,
9–11 pre-
cluding electrophysiological measurements with asymmetric buffer solutions. Such conditions
are often required for ion channel measurements, for example, electrophysiological characteriza-
tion of the potassium channel KcsA requires an acidic pH on one side of the bilayer.
16,17 In a
traditional macro-scale bilayer membrane system,
7,8,17,18 the bilayer is produced across an aper-
ture in a thin hydrophobic material, typically Teﬂon, separating two cups, providing access to
both sides of the bilayer. However, the bilayers are mechanically fragile, and solution exchange
is problematic. Furthermore, large volumes (ml) of electrophysiology buffer are required. This
issue has been addressed by making smaller systems, incorporating micro-channels for solution
exchange.
8,17,19–22 For example, Stimberg et al. described a ﬂow channel, where the microﬂui-
dic channel and bilayer aperture are made separately and glued together and ﬂuid is ﬂown
across the bilayer using a syringe pump.
19 Shao et al. demonstrated a bilayer microﬂuidic plat-
form that enabled rapid perfusion of liquid (>2.5ll/min), with 100ll samples,
21 and Le Piouﬂe
et al. demonstrated an array of wells, each with multiple small bilayers with ﬂuidic access to
both sides, where electrical recordings were performed by moving an Ag/AgCl electrode from
well to well.
13 Bilayers can also be formed with sessile or falling droplets-in-oil, and ﬂow chan-
nels have been integrated into these systems for solution exchange from one side of the
bilayer.
23,24 High-volume ﬂow has been demonstrated with such platforms.
23 Tsuji et al.
described a droplet-interface bilayer system made using two droplets with microchannel perfu-
sion of one droplet.
20 However, all the platforms described above require a syringe pump and a
relatively large volume of electrophysiology buffer, and hence a relatively large amount of the
compounds that potentially modulate channel activity.
In this paper, we demonstrate a novel scalable bilayer lipid membrane (BLM) system based
on micro-ﬂuidic chips. Bilayers are formed across apertures between 50 and 100lm in diameter
that are micro-fabricated in a thin laminate foil. These aperture-suspended bilayers are mechani-
cally stable with a lifetime of many days. Sample ﬂow along the bilayer is realized by passive
pumping from small droplets, where the ﬂow is driven by the difference in Laplace pressure
between two droplets at either end of a microﬂuidic channel.
25,26 For microﬂuidic channels of
dimensions 55 100lm, the ﬂow rate is up to 0.5ll/min, with ll volume droplets. This design
eliminates the need for syringe pumps and tubing, providing a simple and scalable approach for
the delivery of compounds to the bilayers. The platform is compact and is amenable to paralle-
lization with a small footprint, giving a simple automatable system that could be used for high
throughput screening of ion channels, transporters, and nanopores with small amounts of effec-
tor compounds. We demonstrate the utility of the technology through blocking of a-haemolysin
with b-cyclodextrin (b-CD) and polyethylene glycol (PEG). Rapid determination of IC50 curves
is shown for dose-dependent interaction of the potassium channel KcsA with tetraethylammo-
nium (TEA) demonstrating the ability to examine ion channel behaviour in asymmetric environ-
ments (pH).
II. MATERIALS AND METHODS
A. Device design and fabrication
A small (15 15mm), disposable glass chip contains the ﬂuidics and micro-aperture as
shown in Fig. 1. These chips interface with a master board that contains discrete ampliﬁers for
current recording.
27 The chip is made using laminated dry ﬁlm resist to deﬁne both the aperture
and the ﬂow channel (Figs. 1(a) and 1(b)). Fig. 1(d) shows a cross section of the chip showing
the ﬂow channel and two Ag/AgCl electrodes. Fig. 1(e) is a photograph of a device with the
PMMA well that holds the buffer above the bilayer. BLMs are made by painting a lipid-solvent
solution across the aperture. The trans side of the membrane is accessed via the microﬂuidic
channel, while buffer on the cis side is retained within a plastic reservoir of 200ll volume.
Electrical recordings are made using discrete integrated Ag/AgCl electrodes. Each glass chip
can hold up to four bilayers, each of which is recorded in parallel,
27 but in this work we use a
single aperture. Compared with traditional BLM electrophysiology systems,
11,28,29 both the
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recordings.
Details of the microﬂuidic chip fabrication have been described previously
27 (detailed in
the supplementary material Fig. S1 (Ref. 30)). A four mask process was used. The substrate
consisted of a 100mm diameter 700lm thick glass wafer. Electrodes and contact pads were
made from a 200nm thick Au layer, deﬁned using photolithography and wet etching. The sec-
ond mask deﬁnes the Ag/AgCl electrodes. The Ag electrodes were plated for  6min with a
current density of  2mA/cm
2 to give a thickness of around 5–6lm, and were subsequently
chlorinated by immersion in FeCl3 solution for 2min.
31 The ﬁrst dry ﬁlm resist layer (TMMF
S2055 from Tokyo Okha Koygo Co.) was then laminated to deﬁne the micro-well and the
microﬂuidic channel. A second layer of TMMF S2030 was laminated over the ﬁrst layer at
45  C to deﬁne the BLM aperture.
32 To make the surface hydrophobic (for stable bilayers and
control of droplet surface tension), the chips were exposed to a CF4 plasma, at a gas ratio of
2% O2 and 98% CF4, 50W and 50 mTorr pressure for 2min. The contact angle for water on
the treated TMMF surface was around 115 . A hydrophobic surface also ensures that the aque-
ous pumping droplets do not spread. Chips could be re-used after washing with water and iso-
propyl alcohol. After several experiments, the contact angle slowly reduced but chips could be
made hydrophobic again by re-exposure to CF4 plasma. The ﬁnal device is shown in Fig. 1(e)
and is 15 15mm in size. A poly(methyl methacrylate) (PMMA) chamber of dimension
10 4 5mm is glued to the top face to form the cis reservoir.
B. Lipids, reagents, and ion channel reconstitution
All lipids were obtained from Avanti Polar Lipids (Alabaster, AL, USA). The cDNA for
KcsA was chemically synthesised by Euroﬁns MWG Operon (Wolverhampton, UK). N-do-
decyl-b-D maltopyranoside (DDM) and 5-cyclohexyl-1-pentyl-b-D maltoside (Cymal-5) were
FIG. 1. Illustration of the droplet ﬂow BLM chip. (a) 3-D schematic diagram of the chip with a single bilayer aperture,
showing the integrated Ag/AgCl electrodes (one common and one beneath the BLM) and the pumping droplets. (b)
Illustration of the micro well and integrated Ag/AgCl electrode showing the direction of ﬂuid ﬂow which is from the small
droplet to the large droplet. Note that for ease of illustration, the architecture does not correspond exactly to Fig. 1(a). (c)
Diagram demonstrating transient blocking of a-hemolysin by b-cyclodextrin (b-CD) ﬂowing along the trans side of the
bilayer. (d) Cross section of chip showing the bilayer aperture and electrode. The ﬂow channel is 55lm high and 100lm
wide. (e) A fabricated chip showing the pumping and reservoir droplet. Also shown is the plastic compartment that deﬁnes
the top reservoir. Note that (a)–(d) are not to scale.
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were from Sigma-Aldrich (Gillingham, UK).
a-HL was dissolved in 150mM KCl (10mM HEPES pH 7.4) buffer at 0.1mg/ml concen-
tration and 200ll aliquot stored in a  84  C freezer. b-CD and TEA solutions were prepared at
various concentrations in 1M KCl (10mM HEPES pH 7.4) and 150mM KCl (10mM MES pH
4.0) buffers, respectively. PEG 1000 and PEG 10000 were dissolved at the desired concentra-
tion in 3M KCl.
KcsA was cloned into pET28a (Novagen) using NcoI-XhoI restriction sites (NEB). This
generated a C-terminal hexa-His tagged protein, together with a two amino acid insertion (Leu,
Glu) between the distal end of KcsA and the His-tag. A non-inactivating KcsA channel mutant
(E71A) was generated using the QuikChange protocol (Agilent Technologies). The ﬁnal con-
struct was conﬁrmed by sequencing on both strands. KcsA was expressed, puriﬁed, and recon-
stituted into proteoliposomes as previously described.
15,33 The channel/lipid molar ratio in the
proteoliposomes was 1/6000. It is known that the lipid composition modulates KcsA activity,
33
therefore the protein was reconstituted in liposomes and characterized in bilayers of a 1:1 lipid
mixture of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-(10-rac-glycerol) (POPG). Lipids were dissolved in chloroform, mixed in
the correct ratio, and dried in a desiccator later dissolved in decane for bilayer formation.
Unless otherwise speciﬁed for KcsA experiments, the cis chamber contained 150mM KCl,
10mM HEPES pH 7.4, and the trans chamber contained 150mM KCl, 10mM MES pH 4.0 so-
lution. Proteoliposomes with reconstituted KcsA channels were added to the cis side.
C. Bilayer formation
Bilayer capacitance and ion channel current measurements were made using an ID 526
BLM ampliﬁer with a sampling frequency of 5 kHz and all data is presented without ﬁltering.
Potential is measured relative to the cis side. Bilayers were formed as follows: the top compart-
ment was ﬁlled with buffer (e.g., 1M KCl, 10mM HEPES, and pH 7.4) and a slight pressure
was applied to ﬁll the hydrophobic microﬂuidic channel. A 2.5ll and 8ll drop of buffer were
placed at either end of the microﬂuidic channel. Bilayers were made from 1,2-diphytanoyl-sn-
glycero-3-phosphocholine (DPhPC) by painting a 3–5ll droplet of lipid-decane solution
(20mg/ml) with an acrylic ﬁbre brush. Bilayer formation was monitored by capacitance meas-
urements. Bilayer was usually made at the ﬁrst attempt; a further attempt gave nearly 100%
yield. Note that this manual method of forming bilayers could be automated as described.
9 For
a-HL experiments, the protein was added from the cis side (top reservoir) with blocker added
from the trans side (ﬂow channel).
For a 75lm diameter aperture, the capacitance was typically 15–20pF, compared with a
background capacitance of  2–3pF, which is lower than the typical 10pF background capaci-
tance of a conventional septum. Taking a typical speciﬁc capacitance of a bilayer as 0.45lF/
cm
2,
34 this gives an active bilayer area of approximately 70% of the aperture size. If a smaller
bilayer was obtained by painting or if there was no channel insertion within 10min, the bilayer
was broken and reformed to encourage bilayer growth or channel insertion. Without ﬂow,
bilayers were stable for 10 days (maximum length of experiment) as presented by authors in an
earlier piece of work.
27 With a continuous ﬂow of  0.4–0.5ll/min, the bilayers were stable for
several hours.
III. RESULTS AND DISCUSSION
A. Flow rate and bilayer stability
The movement of liquid by surface tension from a small droplet (pumping port) to a large
droplet (reservoir port) has been described by Beebe and co-workers.
25,26 Differences in
Laplace pressure between the two different sized droplets drives the ﬂow. Whilst the surface
area of the droplet on the substrate remains constant, the volumetric ﬂow also remains approxi-
mately constant. The contact angle reduces as ﬂuid is depleted from the pump droplet and
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begins to reduce, until it ﬁnally reaches the area of the port and the ﬂow rate changes.
26
Therefore, a stable ﬂow rate is maintained only when the pump droplet exists in the ﬁrst phase,
i.e., with constant area on the substrate. This means that additional liquid needs to be added to
the pump droplet at regular intervals, usually every 3 min to maintain the maximum ﬂow rate.
Droplet addition was performed using a pipette, but this procedure could be easily automated
with a robotic system. It should be noted that the volume of both droplets can also decrease by
evaporation, however the evaporation rate is insigniﬁcant compared to the ﬂow rate. We deter-
mined the evaporation rate to be 4065min for a 2ll droplet and 80610min for an 8ll drop-
let at ambient conditions (typically 21  C and 50% relative humidity).
The volumetric ﬂow rate during pumping is given by
dV
dt
¼
1
Z
 
qgl  
2c
R
 
; (1)
where Z is the hydrodynamic resistance of the channel, R is the radius of the pumping droplet, q is
the density of the liquid, g is the gravitational acceleration, l is the height of the reservoir droplet,
and c is the surface free energy of the liquid.
25,26 The ﬂow channel resistance Z is given by
Z ¼
12lL
WH3 1   0:63
H
W
   ; (2)
where W, H, and L are the width, height, and length of the ﬂow channel and l is the viscosity
of the liquid. For a reservoir droplet height l¼2mm, the ﬂow rate was calculated for three dif-
ferent channel widths, 70lm, 100lm, and 200lm and a range of pump droplet volumes as
shown in Fig. 2. The channel height in each case was 55lm (i.e., one layer of laminate resist)
with a channel length of 1.7cm.
The ﬂow behaviour was also evaluated experimentally using tracer particles (100nm ﬂuo-
rescent beads). Two droplets of 150mM KCl were placed on the reservoir (8ll) and pump
(2.5ll) ports, and after 3min an additional 1.25ll droplet containing ﬂuorescent beads (0.002%
w/v) was placed on top of the depleted pump droplet. The ﬂuorescence intensity was measured
at the aperture in the absence of a bilayer. Further 1.25ll droplets of buffer (without beads)
were added every 3 min to the pump drop. Addition of the droplet with beads produced an im-
mediate spike in the ﬂuorescence. This intensity decreased exponentially as the channel was
washed with subsequent buffer-only droplets, as shown in Fig. 3. After 15 min of ﬂowing
buffer solution, the ﬂuorescence intensity reduced to <4% of its peak value. With the employed
droplet sizes and channel dimensions (55lm high and 100lm wide), the estimated ﬂow rate
was  0.42ll/min, which is consistent with the prediction of Fig. 2. For a channel length of
FIG. 2. Variation in calculated ﬂow rate vs pump droplet volume. The ﬂow channel is 55lm high and 1.7cm long. The the-
oretical ﬂow rate as a function of pump droplet volume is shown for three different channel widths.
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let 17ll (Ref. 24) and bottom compartment 30ll.
23 Therefore, the device would require signiﬁ-
cantly smaller amount of buffer ( 10ll) to clean the ﬂow channel compare to hundreds of
microlitres in reported work.
23,24
The ﬂow rate was also measured in the presence of a bilayer, whilst simultaneously record-
ing the capacitance (aperture of 75lm, ﬂow channel 70lm wide, 55lm high, and 1.5cm
long). At a ﬂow rate of 0.35ll/s, the sample reaches the bilayer within 10 s (see supplementary
material video S1 (Ref. 30)).
To quantify bilayer rupture probability, bilayers were measured for various sizes of droplets
determined from observations with an optical microscope. Droplet sizes were estimated with
trigonometric function for a spherical cap.
26 After bilayer formation from DPhPC-decane solu-
tion, a droplet was placed at the pumping port and bilayer stability was monitored by capaci-
tance measurements. The number of bilayers tested was >10. Fig. 4 shows the bilayer rupture
probability versus pumping port droplet size. For a droplet of 0.5ll (ﬂow rate  0.6ll/s), the
probability of bilayer breakage was around 50%. For a droplet size of 1ll, the probability
reduced to 25%, and for a 1.5ll droplet it was less than 10% (Fig. 4). For the channel dimen-
sions used in this work (100lm channel width) an initial droplet size of 2.5ll was found to be
optimum, with an addition of a further 1–1.25ll every 3–4min to maintain a stable ﬂow rate
of  0.4ll/min without bilayer rupture.
FIG. 3. Average ﬂuorescence intensity of tracer beads vs time at a constant ﬂow rate of  0.42ll/min. The initial pumping
droplet size was 2.5ll and a 1.25ll drop was added at the pump port every 3 min. The channel width, height, and length
were 100lm, 50lm, and 1.7cm, respectively. Error bars are one S.E.M. for three repeat experiments.
FIG. 4. Rupture probability for a bilayer with different sized droplets at the pumping port. The channel width is 100lm,
the channel width is 55lm, and the channel length is 1.7cm. For each pumping droplet size, the number of measured
bilayers was >10. For droplet volumes>2ll and ﬂow rates of approximately 7 nl/s, the bilayers were stable for hours.
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et al.
21 used a ﬂow system to measure the response of ion channels to inhibitors. With channel
dimensions of 460   120lm, bilayers were stable up to a steady state ﬂow rate of 2.5ll/min
(and up to 20ll/min for a short duration). Considering that the cross section of the channel in
our device is 10 times smaller, this is a similar scaled ﬂow rate. The time required for com-
pounds to reach the bilayer can also be calculated
21 where a switching time is deﬁned as the
time required for the concentration of solute to change from 5% to 95%. At our maximum ﬂow
rate of 0.4ll/min, the switching time (s) for the TEA blocker (D¼5   10
 10 m
2/s)
35 is  4s.
This is shorter than reported for small ions such as La
2þ at much higher ﬂow rates of 10ll/
min,
21 highlighting the advantage of smaller microﬂuidic channels.
B. Ion channel measurements
Dose-dependent blocking of a-hemolysin with b-CD is shown in Fig. 5. After bilayer for-
mation, a-hemolysin pores were incorporated by addition of protein to the cis side reservoir.
Spontaneous insertion of one or two channels occurred after 1–2 min, as shown in Fig. 5(a).
Transient blocking was observed within a few seconds of adding b-CD to the trans side ﬂow
channel of the bilayer via a single droplet (Fig. 5(b)). The frequency of blocking events
increased with b-CD concentration (Figs. 5(b) and 5(c)), consistent with published data.
28 After
ﬂushing with buffer-only solution, very few events a-hemolysin blocking events were observed
(Fig. 5(d)), demonstrating efﬁcient perfusion of the b-CD blocker compound. The blocking fre-
quency was quantiﬁed over discrete time windows of 10s. An event was scored if the current
dropped to a value of 4r below the open pore currents,
36 where the standard deviation r is the
peak-to-peak noise of the baseline current, which was  2pA (Figs. 5(a) and 5(d)). The block-
ing frequency increased with b-CD concentration as shown in Table I, consistent with published
FIG. 5. Flow channel perfusion of b-CD. (a) Current trace of a-hemolysin in the presence of the b-CD blocker, in 1M KCl
buffer. Current traces of a shorter time scale show (b) bilayer insertion of a single a-hemolysin channel, (b) and (c) transient
channel blocking events induced by (c) 100lM b-CD and (d) 500lM b-CD, and (e) the a-hemolysin current without sig-
niﬁcant b-CD blocking after rinsing the ﬂow channel with buffer-only solution. The applied potential was þ50mV and the
sampling frequency was 5 kHz, with no additional ﬁltering.
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28,37 Bilayers were stable with no breakage during all these experiments, which could con-
tinue for several hours.
Transient blocking of a-hemolysin with two different PEG molecules is shown in Fig. 6.A
buffer solution of 3M KCl was used to maximize polymer-pore attraction.
38 The a-hemolysin
protein was added to the cis compartment. PEG solutions (0.5mg/ml (Ref. 39)) were introduced
via the trans (bottom) channel (PEG 1000, followed by clean buffer, then PEG 10000).
Spontaneous blocking events were observed with PEG 1000 as shown in Fig. 6(a) (see supple-
mentary material Fig. S2 for a long time trace
30); residual currents were around 14%–18% of
the open pore current, as previously observed.
38 Ion channel exposure to the higher molecular-
weight PEG (PEG 10000) further reduced the residual current to  4%–6% of the open pore
current (Fig. 6(b)), conﬁrming that the amplitude of the blockage varies with the molecular
weight of the PEG.
38 Histograms of blocking events are shown in Figs. 6(c) and 6(d) for PEG
TABLE I. Frequency of a-hemolysin blocking events for the ﬂow channel sequence buffer solution–100 lM
b-CD–500lM b-CD–buffer solution. Data are taken from 10s bins. An event is scored positive when the current is 4r
below the open pore current, where r is approximately 2pA. The error bar is the standard deviation from three separate
experiments.
b-CD concentration (lM) Number of events/s (mean) Standard deviation (6)
0 (at start) 0 0
100 10.24 1.46
500 38.88 2.42
0 (after clean) 0.96 0.2
FIG. 6. Blocking of a-hemolysin channels by PEG in 3M KCl solution at 20mV. (a) Single blocking events due to PEG
1000 shown for two different time scales. (b) Normalised current trace showing blocking of a single a-HL pore in the pres-
ence of PEG 1000, followed by clean buffer, then after the introduction of PEG 10000. The open pore current and the cur-
rent after blocking by PEG are highlighted by the arrows. Current histograms of blocking events are shown in (c) for PEG
1000 and (d) for PEG 10000. For each histogram, a 5s duration trace was chosen, with bin width 0.001pA (data processed
with Clampﬁt software). Sampling frequency for all recordings was 5 kHz, with no additional ﬁltering. I0 is the open pore
current and I is the current with PEG blocker.
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cule to be rapidly correlated with current block levels and bilayer current histograms.
Finally, to demonstrate ion channel incorporation by vesicle fusion and asymmetric electro-
physiology buffer experiments, current traces were recorded for the pH-gated ion channel
KcsA.
16 Following formation of stable bilayers,  2.5ll of proteoliposome dispersion was
added to the cis chamber. Only those channels that insert with the intracellular side facing the
trans (pH 4.0) chamber will be active; channels inserting with the intracellular side facing the
cis (pH 7.4) chamber will be functionally silent.
16,17,32 Characteristically, KcsA displays long-
lived “quiet” or closed intervals and exhibits low open probabilities,
16 hence we used the non-
inactivating KcsA mutant (E71A) where the long closures have been abolished and the open
probability is >90%.
40 Single-channel KcsA-E71A traces in symmetrical 150mM KCl solutions
were obtained, demonstrating proteoliposome fusion with the aperture-suspended bilayer and
bilayer incorporation of a non-toxin ion channel. Selected traces and a current voltage relation-
ship derived from a larger data set are shown in Fig. 7 and are in agreement with published
results.
40,41
The ﬂow channel was subsequently utilized to expose bilayer-incorporated KcsA-E71A to
a sequence of solutions, of increasing concentration, of the potassium channel blocker tetraeth-
ylammonium (TEA
þ).
17,40 Concentration-dependent modulation of KcsA activity was observed,
summarised in Fig. 7(d), and analysis gave an IC50 value of 13.6mM, correlating with litera-
ture.
40 Signiﬁcantly, the modulation of E71A-KcsA activity by TEA was characterized using
only 100lg of compound (15ll volume) in 30 min.
IV. CONCLUSION
We have developed a compact, simple, and scalable planar bilayer chip technology based
on micro-cavities with integrated electrodes and microﬂuidic passive ﬂow. The bilayer chips
are simple to manufacture from dry ﬁlm resist and the passive pumping method eliminates the
need for unwieldy syringe pumps and tubes with associated material wastage.
7,8,19 The
FIG. 7. Electrophysiological measurements with KcsA-E71A ion channel, incorporated in the on-chip aperture-suspended
bilayer by vesicle fusion. The cis reservoir contains 150mM KCl, 10mM HEPES pH 7.4 buffer, and the trans ﬂow channel
contains 150mM KCl, 10mM MES pH 4.0 buffer. Current traces recorded at (a) þ50mV and (b) þ75mV display single-
channel KcsA gating events. (c) Current-voltage relationship for KcsA single-channel conductance. Error bars are standard
deviations obtained from four separate bilayers. (d) Normalised ion-channel conductance for different TEA
þ blocker con-
centrations in the trans ﬂow channel. Fitting to the Hill equation gives an IC50 value of 13.6mM. The bilayer aperture for
(a)–(c) was 60lm and for (d) 75lm.
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152.78.66.19 On: Fri, 09 Jan 2015 14:21:41perfusion system was demonstrated using three model systems: (1) a-HL insertion on the cis
side, with b-CD blocker introduced to and ﬂushed out of the trans ﬂow channel, (2) a-HL tran-
sient blocking with different molecular weight PEGs via the ﬂow channel, and (3) KcsA-E71A
proteoliposome fusion from the cis compartment, and concentration-dependent TEA
þ blocking
of the bilayer-incorporated KcsA mutant from the ﬂow channel. Compared with traditional
bilayer electrophysiology systems,
28,29 which use large-volume cups and an aperture in a Teﬂon
septum, both the bilayer and the shunt capacitance are considerably reduced, resulting in higher
quality electrical recordings (see supplementary material Fig. S3 (Ref. 30)). Although our sys-
tem does not require continuous pumping of liquids with pumps and the associated tubing,
nevertheless discrete ll droplets must be added to the device to maintain a constant ﬂow. At
the ﬂow rates described here, this amounts to a droplet every few minutes, a process which
could be easily automated with the use of a micro-pipetting robot system. We believe that this
method provides a simple and efﬁcient way of delivering compounds to ion channels, transport-
ers, or nanopores incorporated in phospholipid bilayers. In contrast to conventional bilayer tech-
nology, the method provides a novel means of drug screening against ion channels using very
small volumes of compound solutions (10–15ll) compared to the state of the art,
19–23 signiﬁ-
cantly reducing the cost per screen. The chips are easy to manufacture on a wafer and could be
reused if necessary. The use of dry ﬁlm resists for chip manufacture gives an aperture with low
shunt capacitance and a microﬂuidic channel of the appropriate dimensions in a single fabrica-
tion step. The bilayers are mechanically very stable enabling solution exchange without ruptur-
ing the bilayer up to 7 nl/s. Although we used passive droplet pumping for these chips, they
could equally be interface with conventional microﬂuidic pumping systems if so desired. The
system is ideal for parallel electrophysiology assays and provides a novel tool for drug screen-
ing, where a range of target compounds could be quickly titrated against different membrane
proteins.
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